Statins May Lower Dementia Risk by 15%. The Earlier You Start, the Better.
A man in his early 60s came in for a cholesterol check. His LDL was 142. I recommended a statin. He declined — said he did not want to be on a maintenance drug. Six years later, his memory started going.
That is not a controlled trial. That is not data. But it is the kind of thing that sits in your head when a study like this one comes out.
The Study
Researchers at Copenhagen University Hospital tracked 132,585 adults with type 2 diabetes in Denmark over 15 years — 2006 to 2021. All were statin-free at the start. The question: does when you start matter?
It did.
- Early statin initiation: 15% lower relative risk of dementia over 10 years
- Late statin initiation: 10% lower relative risk
- Overall dementia rate: 2.7% of the cohort developed dementia
The earlier you start, the bigger the benefit. Results were similar in women and men.
The study was presented at the European Society of Cardiology congress in Munich on August 30 and published simultaneously in Lancet Regional Health Europe.
Why the Timing Matters
The brain findings are consistent with what we know about LDL cholesterol and vascular health. High LDL drives atherosclerosis — plaque in arteries. That does not only affect the coronary arteries. It affects the blood vessels supplying the brain. Repeatedly disrupted cerebral perfusion — even at levels that do not cause a stroke — may accelerate cognitive decline.
Lead author Dr. Tummas Ternhamar put it plainly: detecting and treating high LDL cholesterol from midlife is one of the modifiable risk factors the Lancet Dementia Commission has already flagged. This study strengthens the timing argument within that picture.
What This Does Not Prove
This is observational data. The researchers tracked people who chose to start statins versus those who did not — they did not randomize. That means there is still the possibility of confounding: people who start statins early may also be more engaged with their health overall.
The British Heart Foundation chief scientific officer was appropriately cautious: association, not causation, is proven here. The mechanism is biologically plausible, but we do not have randomized trial data showing statins directly prevent dementia in otherwise healthy adults.
The Clinical Take
First, the statin-for-brain-health argument is not brand new. The concept that cardiovascular risk factors contribute to cognitive decline has been in the literature for years. What is new here is the scale — 132,585 people, 15 years, and a clear dose-response pattern by timing.
Second, for patients already on statins for cardiovascular indications, this is reinforcement, not a new reason. If you are on a statin for lipid management or ASCVD, the dementia angle is a bonus reason to stay on it — not a new reason to start.
Third, for the patient who is hesitant about statins: this is useful context. The conversation about starting a statin typically focuses on heart attacks and strokes 10 to 20 years from now. Dementia is closer, more tangible, and scarier to most patients. That is not a scare tactic — it is a legitimate framing update.
Bottom Line
A 15-year observational study does not settle the causation question. But it adds meaningful real-world evidence to a biologically plausible story: lowering LDL cholesterol early may protect the brain as well as the heart. The dose-response pattern — acting early is better than acting late — is exactly what you would expect if the mechanism is vascular.
If you have high LDL, type 2 diabetes, or a family history of early cardiovascular disease, this is one more reason to take the conversation about statins seriously. The cognitive benefit, if it holds in randomized trials, would be enormous.
Sources:
- Ternhamar T et al. Lancet Regional Health Europe. Presented August 30, 2026 at ESC Congress, Munich.
- The Guardian, August 30, 2026. Statins can reduce dementia risk by up to 15%.
- Lancet Dementia Commission (2024): 14 modifiable risk factors, 45% of dementia cases potentially preventable.